Log In
Print
BCIQ
Print
Print this Print this
 

Provenge, sipuleucel-T

Also known as: APC8015

  Manage Alerts
Collapse Summary General Information
Company Dendreon Corp.
DescriptionAutologous dendritic cells loaded with a fusion protein of prostatic acid phosphatase and an immunostimulatory cytokine
Molecular Target Not applicable
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentMarketed
Standard IndicationProstate cancer
Indication DetailsNeoadjuvant treatment in patients with localized prostate cancer; Treat advanced androgen-independent prostate cancer (AIPC); Treat advanced castration-resistant prostate cancer (CRPC); Treat advanced prostate cancer; Treat androgen-dependent prostate cancer; Treat androgen-independent prostate cancer (AIPC); Treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (CRPC) in adults in whom chemotherapy is not yet clinically indicated; Treat asymptomatic or minimally symptomatic metastatic hormone refractory prostate cancer; Treat asymptomatic, metastatic, castration-resistant prostate cancer (CRPC); Treat castration-resistant prostate cancer (CRPC); Treat early stage prostate cancer; Treat metastatic castration-resistant prostate cancer (CRPC); Treat non-metastatic androgen-dependent prostate cancer; Treat non-metastatic prostate cancer patients with rising prostate-specific antigen (PSA) levels after primary therapy; Treat prostate cancer
Regulatory Designation

EU - Standard Review (Treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (CRPC) in adults in whom chemotherapy is not yet clinically indicated)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today